NASDAQ:TVGN Tevogen Bio Q2 2026 Earnings Report $6.72 +0.11 (+1.59%) Closing price 03:59 PM EasternExtended Trading$6.48 -0.24 (-3.64%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tevogen Bio EPS ResultsActual EPS-$1.52Consensus EPS -$2.53Beat/MissBeat by +$1.01One Year Ago EPSN/ATevogen Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATevogen Bio Announcement DetailsQuarterQ2 2026Date8/14/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsTevogen Bio's next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Tevogen Bio Earnings HeadlinesTevogen Regains Compliance with Nasdaq Global Market Continued Listing RequirementsSeptember 30 at 4:30 PM | globenewswire.comTevogen Bio (NASDAQ:TVGN) Stock Price Up 5.1% - Time to Buy?September 23, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 1 at 1:00 AM | Altimetry (Ad)Tevogen Bio Holdings Rebrands as Tevogen Inc.July 30, 2026 | tipranks.comTevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGNJuly 24, 2026 | benzinga.comTevogen Bio Announces 2026 Annual Meeting of StockholdersJuly 13, 2026 | globenewswire.comSee More Tevogen Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tevogen Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tevogen Bio and other key companies, straight to your email. Email Address About Tevogen BioTevogen Bio (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing precision T-cell therapies for patients with viral infections and cancer. The company’s approach uses antigen-specific cytotoxic T lymphocytes designed to recognize and eliminate infected or abnormal cells while seeking to provide an “off-the-shelf” treatment option. Tevogen’s pipeline is built around its ExacTcell platform, which is intended to support the development and manufacturing of targeted cellular immunotherapies. Its lead program, TVGN 489, is an investigational, SARS-CoV-2-specific T-cell therapy being developed for immunocompromised patients who may remain vulnerable to COVID-19. The therapy is not approved for commercial use. Tevogen was founded by physician and biotechnology executive Dr. Ryan Saadi, who serves as the company’s chairman and chief executive officer. The company is based in Warren, New Jersey, and is developing therapies for potential use in the United States and other markets, subject to clinical development and regulatory approvals. Tevogen became a publicly traded company through a business combination with Semper Paratus Acquisition Corporation.View Tevogen Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
